Dividend Win Wednesday: Semiconductor Capital at 85% Off and Insiders Buying Energy
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.
Sign in →6. Biogen Inc. (BIIB)
Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: -3.7% (near high)
Biogen trades at a 6.2% free cash flow yield with 75.7% gross margins and $84.2 million in net insider purchases over six months, the largest dollar accumulation in this week's screen. The company sits 3.7% above its 52-week high (near-high zone) at a 23.0 forward multiple while analysts project modest 2.7% upside to $219.44 from the current $213.66 price.
Three insiders filed Form 4 purchases on June 11: Mantas Jesus B, Minor Lloyd, and Freire Maria C, with insider buy transactions representing 50.4% of all activity versus 2.0% sells. Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the U.S. in partnership with Harrow on June 30, expanding the biosimilar franchise while Biogen maintains a 6.4× interest coverage ratio and 0.64× net debt to EBITDA.
Biogen pays no dividend despite a 70.2% ROIC, choosing instead to deploy capital into pipeline investments and share repurchases; the lack of income return removes a key risk buffer if the stock corrects from near-high levels. Next earnings land July 29 with $2.09 EPS expected on $2.4 billion revenue; consensus negative $7.16 EPS for the August 6 period reflects accounting treatment, not operational cash flow.
7. Exxon Mobil Corporation (XOM)
Dividend yield: 3.0% | Payout ratio: 59.2% | 52w drawdown: 23.2%
Exxon posts a 4.2% free cash flow yield and 11.1% ROIC at a 22.8 forward multiple, trading 23% below its 52-week high while maintaining a 69.4× interest coverage ratio and 0.70× net debt to EBITDA. The company's shareholder yield of 3.3% (dividend plus buybacks) underpins capital return even as revenue declined 4.5% year-over-year and the five-year dividend growth rate turned negative at -10.0%, reflecting the 2020 pandemic cut.
Insiders purchased $5.04 million net over six months, adding 32,250 shares with buy transactions at 1.5% versus 0.6% sells. Sable Offshore raised $300 million via notes and a share offering to repay an Exxon loan on June 30, a downstream financing event that reduces counterparty exposure while Exxon redirects capital to upstream and chemicals.
Analysts project $169.91 upside (25.3% above the $135.57 price) contingent on a recovery in global refining margins and crude price stabilization; the integrated model provides ballast but limits torque to upstream-only plays. Next earnings hit July 31 with $3.73 EPS expected on $101.5 billion revenue.
8. Gilead Sciences, Inc. (GILD)
Dividend yield: 2.6% | Payout ratio: 47.9% | 52w drawdown: 20.7%
Gilead delivers a 6.1% free cash flow yield with 78.8% gross margins and 24.4% ROIC, trading 21% below its 52-week high at a 17.0 forward multiple while analysts project $157.83 upside (26.5% above the $124.78 price). The company grew revenue 2.4% year-over-year and maintains a 10.6× interest coverage ratio with 0.84× net debt to EBITDA, supporting a 47.9% payout ratio on a 1.2% shareholder yield.
Insiders added $6.14 million net over six months, purchasing 283,785 shares with Form 4 filings from Dickinson Andrew D (June 11 and June 16) and Mercier Johanna (June 16); buy transactions represented 53.0% of activity versus 30.1% sells. The FDA approved Trodelvy for triple-negative breast cancer in June, expanding the oncology franchise and reinforcing the 14.7% normalized 10-year earnings yield.
Consensus projects negative $7.16 EPS for the August 6 earnings date, an accounting artifact from acquisition charges; core operations remain cash-generative, but the headline figure will distort media coverage. Revenue estimate of $7.4 billion assumes continued HIV and oncology momentum without material pipeline setbacks.
What to Watch
-
July 21 (Novartis), July 23 (Newmont), July 29 (Biogen, KLA), July 30 (KLA), July 31 (Exxon), August 4 (EOG), August 6 (ConocoPhillips, Gilead): Eight earnings releases across energy, metals, pharma, and biotech will test whether Q2 cash flow supports current payout ratios or triggers analyst estimate cuts.
-
July CPI and FOMC minutes (mid-month): If inflation prints softer, the 10Y Treasury yield could compress further, widening yield spreads for high-FCF energy and pharma names and potentially pulling capital back into dividend stocks from money-market funds.
-
Samsung/SK Hynix capital deployment updates (ongoing): The $1.3 trillion Korea semiconductor build-out announced June 30 is a multi-year tailwind for KLA; watch for equipment order announcements or fab construction timelines that confirm 2026-2027 revenue visibility.
-
Gold price action through Q3: Newmont's 31% drawdown and 53% analyst upside assume gold stabilizes after its worst quarterly selloff in 13 years; a further leg down breaks the thesis, while a rebound to $2,100+ per ounce could accelerate the stock 20%+ in weeks.
Go Deeper
The dividend screener ranks companies by free cash flow yield, payout sustainability, insider conviction, and drawdown opportunity.
Check out the full screener →
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full dividend screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →